As breast cancer is a heterogeneous disease, our study cohort of only 70 breast cancer patients is unfortunately not able to adequately analyze the role of platelet-derived ADAM17 in different breast cancer subgroups (Supplementary Figure S1). Here, ADAM17 is linked to breast cancer.